[Poster] What’s the Best Way to Measure Absolute Bioavailability?

Traditionally, absolute bioavailability ( has been determined using a crossover study design, requiring administration of an IV dose expected to give plasma concentrations similar to those arising from the therapeutic extravascular (EV) dose. An alternative approach is to administer an isotopically labelled IV microtracer dose concomitantly with the EV dose (see Figure 1 This methodology is both scientifically superior and more resource efficient With the inclusion of ABA data mandatory for marketing applications submitted to the Australian TGA 1 and other regulators increasingly asking for this information, a growing number of such studies are being conducted